JPWO2021157634A1 - - Google Patents
Info
- Publication number
- JPWO2021157634A1 JPWO2021157634A1 JP2021575844A JP2021575844A JPWO2021157634A1 JP WO2021157634 A1 JPWO2021157634 A1 JP WO2021157634A1 JP 2021575844 A JP2021575844 A JP 2021575844A JP 2021575844 A JP2021575844 A JP 2021575844A JP WO2021157634 A1 JPWO2021157634 A1 JP WO2021157634A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020018249 | 2020-02-05 | ||
| JP2020018249 | 2020-02-05 | ||
| PCT/JP2021/004018 WO2021157634A1 (ja) | 2020-02-05 | 2021-02-04 | タウオパチーおよび認知症関連疾患の判定薬および判定方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021157634A1 true JPWO2021157634A1 (https=) | 2021-08-12 |
| JPWO2021157634A5 JPWO2021157634A5 (https=) | 2024-01-18 |
| JP7752533B2 JP7752533B2 (ja) | 2025-10-10 |
Family
ID=77199622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575844A Active JP7752533B2 (ja) | 2020-02-05 | 2021-02-04 | タウオパチーおよび認知症関連疾患の判定薬および判定方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230349924A1 (https=) |
| EP (1) | EP4101465A4 (https=) |
| JP (1) | JP7752533B2 (https=) |
| KR (1) | KR20220137674A (https=) |
| CN (1) | CN115066610A (https=) |
| AU (1) | AU2021217290A1 (https=) |
| CA (1) | CA3168823A1 (https=) |
| MX (1) | MX2022009607A (https=) |
| TW (1) | TWI853145B (https=) |
| WO (1) | WO2021157634A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| AU2019318888A1 (en) | 2018-08-07 | 2021-03-18 | Sumitomo Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003521499A (ja) * | 2000-01-24 | 2003-07-15 | インノジェネティクス・エヌ・ブイ | タウオパチーの診断 |
| WO2012091138A1 (ja) * | 2010-12-28 | 2012-07-05 | 大日本住友製薬株式会社 | アルツハイマー病の診断薬及び診断方法 |
| JP2017042172A (ja) * | 2011-09-19 | 2017-03-02 | アクソン ニューロサイエンス エスエー | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2017506068A (ja) * | 2014-01-28 | 2017-03-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | リン酸化タウタンパク質を指向するラクダ科動物単一ドメイン抗体及びその接合体を製造する方法 |
| JP2017113004A (ja) * | 2010-10-07 | 2017-06-29 | エーシー イミューン エス.エー. | 薬学的組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| ATE514707T1 (de) * | 2002-04-19 | 2011-07-15 | Univ Toronto | Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer |
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| EP1963534A2 (en) * | 2005-12-19 | 2008-09-03 | Genizon Biosciences Inc. | Genemap of the human gene associated with crohn's disease |
| JP7148776B2 (ja) | 2018-08-02 | 2022-10-06 | 国立大学法人山梨大学 | コロニー識別システム、コロニー識別方法およびコロニー識別プログラム |
| AU2019318888A1 (en) * | 2018-08-07 | 2021-03-18 | Sumitomo Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
-
2021
- 2021-02-04 CN CN202180013030.4A patent/CN115066610A/zh active Pending
- 2021-02-04 MX MX2022009607A patent/MX2022009607A/es unknown
- 2021-02-04 AU AU2021217290A patent/AU2021217290A1/en not_active Abandoned
- 2021-02-04 KR KR1020227029345A patent/KR20220137674A/ko not_active Withdrawn
- 2021-02-04 CA CA3168823A patent/CA3168823A1/en active Pending
- 2021-02-04 US US17/794,912 patent/US20230349924A1/en active Pending
- 2021-02-04 EP EP21750738.3A patent/EP4101465A4/en not_active Withdrawn
- 2021-02-04 JP JP2021575844A patent/JP7752533B2/ja active Active
- 2021-02-04 TW TW110104245A patent/TWI853145B/zh active
- 2021-02-04 WO PCT/JP2021/004018 patent/WO2021157634A1/ja not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003521499A (ja) * | 2000-01-24 | 2003-07-15 | インノジェネティクス・エヌ・ブイ | タウオパチーの診断 |
| JP2017113004A (ja) * | 2010-10-07 | 2017-06-29 | エーシー イミューン エス.エー. | 薬学的組成物 |
| WO2012091138A1 (ja) * | 2010-12-28 | 2012-07-05 | 大日本住友製薬株式会社 | アルツハイマー病の診断薬及び診断方法 |
| JP2017042172A (ja) * | 2011-09-19 | 2017-03-02 | アクソン ニューロサイエンス エスエー | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2017506068A (ja) * | 2014-01-28 | 2017-03-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | リン酸化タウタンパク質を指向するラクダ科動物単一ドメイン抗体及びその接合体を製造する方法 |
Non-Patent Citations (1)
| Title |
|---|
| J ALZHEIMERS DIS, vol. 71, no. 4, JPN6023026073, 15 October 2019 (2019-10-15), pages 1163 - 1174, ISSN: 0005641184 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4101465A1 (en) | 2022-12-14 |
| TW202136297A (zh) | 2021-10-01 |
| AU2021217290A1 (en) | 2022-07-21 |
| CA3168823A1 (en) | 2021-08-12 |
| EP4101465A4 (en) | 2024-03-06 |
| US20230349924A1 (en) | 2023-11-02 |
| CN115066610A (zh) | 2022-09-16 |
| WO2021157634A1 (ja) | 2021-08-12 |
| TWI853145B (zh) | 2024-08-21 |
| JP7752533B2 (ja) | 2025-10-10 |
| MX2022009607A (es) | 2022-09-02 |
| KR20220137674A (ko) | 2022-10-12 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240110 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250425 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250723 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250909 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250930 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7752533 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |